CAML WEBSITES - CARDIOLOGY
The AFFIRM-AHF study demonstrated that treatment with IV iron carboximaltose, in patients stabilized after an episode of acute heart failure (HF) and with iron deficit, was effective in reducing the risk of hospitalization for HF, with a favorable safety profile. In order to know the relevance of the study and the significance of its findings for the current national panorama, My Cardiologia interviewed Prof. Doctor Dulce Brito, coordinator of the telemonitoring project for patients with HF and the RICA-AHF program.
To access the full interview click here.
